Zonsun Pharmaceutical: Clinical trials of new indications for RAY1225 injection, a subsidiary of the company, have been approved.

On the evening of January 23, Zhongsheng Pharmaceutical announced that its holding subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., independently developed an innovative peptide drug RAY1225 injection solution. The Phase III clinical trial of the drug for the treatment of "obesity combined with obstructive sleep apnea" has been approved by the National Medical Products Administration. The company has received the "Notice of Drug Clinical Trial Approval" and is allowed to carry out clinical trials for the new indication of RAY1225 injection solution.